VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, today announced changes to its Board of Directors, effective immediately. Mr. Janusz Grabski has resigned from the Board, and the Board has formally appointed Thomas Mehrling, M.D., Ph.D., the Company's Chief Executive Officer, as a director, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure that the Board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the Company's clinical development and broader corporate objectives. The Board thanked Mr. Grabski for his service and contributions and wished him success in his future endeavors.
The appointment of Dr. Mehrling, who has led the Company since 2023, brings his extensive experience in oncology drug development and corporate strategy directly to the boardroom. This move aligns leadership with governance, potentially streamlining decision-making processes as Helix advances its pipeline. The company's lead candidate, L-DOS47, is an antibody-enzyme conjugate in clinical development for non-small cell lung cancer (NSCLC), targeting an area of high unmet medical need. Additionally, Helix is developing LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The board changes come at a pivotal time for Helix, as it integrates assets from the Laevoroc acquisition and prepares for potential regulatory milestones. The inclusion of the CEO on the board could enhance alignment between management and oversight, ensuring that strategic initiatives are well-coordinated. This restructuring may also signal to investors a commitment to strong governance as the company seeks to advance its clinical programs and create shareholder value.
Helix BioPharma is listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit the company's website at https://www.helixbiopharma.com/. The strategic acquisition from Laevoroc Group, which brought LEUMUNA and GEMCEDA into Helix's pipeline, is detailed in a reference available at Helix BioPharma secures pre-IND candidates LEUMUNA and GEMCEDA in strategic acquisition from Laevoroc Group.
